{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T14:54:50Z","timestamp":1791298490711,"version":"4.1.0"},"reference-count":41,"publisher":"Oxford University Press (OUP)","issue":"3","license":[{"start":{"date-parts":[[2023,5,12]],"date-time":"2023-05-12T00:00:00Z","timestamp":1683849600000},"content-version":"vor","delay-in-days":1,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"name":"National Cancer Control Programme"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,28]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Management options for the treatment of melanoma have expanded in recent years. In an era of promising, but expensive novel pharmacological treatments, robust stage-specific melanoma-related cost estimates are necessary to support budgetary planning, evaluation of cost-effectiveness and to contribute to the investment case for prevention.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A detailed decision model, describing the melanoma care pathway (by disease stage) from diagnosis, through treatment and follow-up was developed over a 5-year time frame from the perspective of the Irish healthcare system. The model was populated with real-world data from the National Cancer Registry Ireland. Uncertainty was explored using one-way and probabilistic sensitivity analysis.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The cost of managing a case of melanoma diagnosed at Stage IV (\u20ac122\u00a0985) was more than 25 times more expensive than managing a case diagnosed at Stage IA (\u20ac4269). Total costs were sensitive to the choice of immunotherapeutic and targeted drug, duration of treatment and proportion of patients receiving immunotherapy agents.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>The rising incidence of melanoma and high cost of new novel therapies presents an immediate challenge to cancer control and public health globally. This study highlights the cost differential between early and late detection and the potential return on investment for prevention versus high-cost treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/pubmed\/fdac154","type":"journal-article","created":{"date-parts":[[2023,5,11]],"date-time":"2023-05-11T21:16:24Z","timestamp":1683839784000},"page":"714-722","source":"Crossref","is-referenced-by-count":20,"title":["Melanoma-related costs by disease stage and phase of management in Ireland"],"prefix":"10.1093","volume":"45","author":[{"given":"Grainne E","family":"Crealey","sequence":"first","affiliation":[{"name":"Clinical Costing Solutions , Belfast BT15 4EB , UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Caitriona","family":"Hackett","sequence":"additional","affiliation":[{"name":"Tallaght University Hospital , Tallaght, Dublin 24 D24 NR0A , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine","family":"Harkin","sequence":"additional","affiliation":[{"name":"HSE National Cancer Control Programme (NCCP), King\u2019s Inns House , 200 Parnell Street, Dublin 1 DO1 A3Y8 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patricia","family":"Heckmann","sequence":"additional","affiliation":[{"name":"HSE National Cancer Control Programme (NCCP), King\u2019s Inns House , 200 Parnell Street, Dublin 1 DO1 A3Y8 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fergal","family":"Kelleher","sequence":"additional","affiliation":[{"name":"St. James and Tallaght University Hospitals , Department of Medicine, , Dublin 2 D02 R590 , Ireland"},{"name":"Trinity College Dublin , Department of Medicine, , Dublin 2 D02 R590 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1ine","family":"Lyng","sequence":"additional","affiliation":[{"name":"HSE National Cancer Control Programme (NCCP), King\u2019s Inns House , 200 Parnell Street, Dublin 1 DO1 A3Y8 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Triona","family":"McCarthy","sequence":"additional","affiliation":[{"name":"HSE National Cancer Control Programme (NCCP), King\u2019s Inns House , 200 Parnell Street, Dublin 1 DO1 A3Y8 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria","family":"McEnery","sequence":"additional","affiliation":[{"name":"HSE National Cancer Control Programme (NCCP), King\u2019s Inns House , 200 Parnell Street, Dublin 1 DO1 A3Y8 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Clare","family":"Meaney","sequence":"additional","affiliation":[{"name":"National Cancer Control Programme (NCCP), King\u2019s Inn House , 200 Parnell Street, Dublin, D01 A3Y8 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Darren","family":"Roche","sequence":"additional","affiliation":[{"name":"Sligo General Hospital , Sligo F91H684 , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anne-Marie","family":"Tobin","sequence":"additional","affiliation":[{"name":"Tallaght University Hospital , Tallaght, Dublin 24 D24 NR0A , Ireland"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2023,5,11]]},"reference":[{"key":"2023083113304300500_ref1","volume-title":"European Commission","author":"European Cancer Information System (ECIS)"},{"issue":"5","key":"2023083113304300500_ref2","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1001\/jamadermatol.2022.0160","article-title":"Global burden of cutaneous melanoma in 2020 and projections to 2040","volume":"158","author":"Arnold","year":"2022","journal-title":"JAMA Dermatol"},{"key":"2023083113304300500_ref3","volume-title":"Skin Cancer Prevention Plan, 2019-2022","author":"Department of Health, Ireland"},{"issue":"2","key":"2023083113304300500_ref4","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1097\/CEJ.0000000000000056","article-title":"Health system costs of skin cancer and cost-effectiveness of skin cancer prevention and screening: a systematic review","volume":"24","author":"Gordon","year":"2015","journal-title":"Eur J Cancer Prev"},{"key":"2023083113304300500_ref5","volume-title":"Cancer Incidence Projections for Ireland 2020-2045","author":"National Cancer Registry","year":"2019"},{"issue":"4","key":"2023083113304300500_ref6","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.3390\/cancers12041003","article-title":"Healthcare costs of metastatic cutaneous melanoma in the era of immunotherapeutic and targeted drugs","volume":"12","author":"Leeneman","year":"2020","journal-title":"Cancers"},{"issue":"5","key":"2023083113304300500_ref7","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.amepre.2012.07.031","article-title":"Melanoma treatment costs: a systematic review of the literature, 1990-2011","volume":"43","author":"Guy","year":"2012","journal-title":"Am J Prev Med"},{"issue":"Suppl 2","key":"2023083113304300500_ref8","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1111\/jdv.15313","article-title":"Modelling first-year cost-of-illness of melanoma attributable to sunbed use in Europe","volume":"33","author":"Krensel","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023083113304300500_ref26","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ejca.2015.09.016","article-title":"Melanoma burden by melanoma stage: assessment through a disease transition model","volume":"53","author":"Tromme","year":"2016","journal-title":"Eur J Cancer"},{"issue":"5 Pt 1","key":"2023083113304300500_ref9","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1016\/S0190-9622(98)70195-1","article-title":"An estimate of the annual direct cost of treating cutaneous melanoma","volume":"38","author":"Tsao","year":"1998","journal-title":"J Am Acad Dermatol"},{"issue":"4","key":"2023083113304300500_ref10","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1017\/S0266462303000709","article-title":"Skin diseases caused by ultraviolet radiation: the cost of illness","volume":"19","author":"Nilsson","year":"2003","journal-title":"Int J Technol Assess Health Care"},{"issue":"1","key":"2023083113304300500_ref11","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1097\/CMR.0b013e3282f36203","article-title":"The economic burden of melanoma in France: assessing healthcare use in a hospital setting","volume":"18","author":"Chevalier","year":"2008","journal-title":"Melanoma Res"},{"issue":"Suppl 3","key":"2023083113304300500_ref12","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1111\/j.1365-2133.2009.09457.x","article-title":"Inpatient management of patients with skin cancer in Germany: an analysis of the nationwide DRG-statistic 2005-2006","volume":"161","author":"Stang","year":"2009","journal-title":"Br J Dermatol"},{"issue":"5","key":"2023083113304300500_ref13","doi-asserted-by":"crossref","first-page":"467","DOI":"10.2340\/00015555-0523","article-title":"Societal cost of skin cancer in Sweden in 2005","volume":"88","author":"Tingh\u00f6g","year":"2008","journal-title":"Acta Derm Venereol"},{"issue":"3","key":"2023083113304300500_ref14","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1007\/s10198-008-0127-0","article-title":"Cost of skin cancer in England","volume":"10","author":"Morris","year":"2009","journal-title":"Eur J Health Econ"},{"key":"2023083113304300500_ref15","volume-title":"The Costs of Skin Cancer to New Zealand","author":"O\u2019Dea","year":"2009"},{"issue":"3","key":"2023083113304300500_ref16","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1590\/S0365-05962009000300004","article-title":"An estimate of the cost of treating melanoma disease in the state of Sao Paulo - Brazil","volume":"84","author":"Souza","year":"2009","journal-title":"An Bras Dermatol"},{"issue":"3","key":"2023083113304300500_ref17","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1001\/archdermatol.2009.389","article-title":"Economic burden of melanoma in the elderly population: population-based analysis of the Surveillance, Epidemiology, and End Results (SEER)--Medicare data","volume":"146","author":"Seidler","year":"2010","journal-title":"Arch Dermatol"},{"issue":"4","key":"2023083113304300500_ref18","doi-asserted-by":"crossref","first-page":"657","DOI":"10.1590\/S0365-05962011000400005","article-title":"An estimate of the cost of treating non-melanoma skin cancer in the state of S\u00e3o Paulo, Brazil","volume":"86","author":"Souza","year":"2011","journal-title":"An Bras Dermatol"},{"issue":"11","key":"2023083113304300500_ref19","doi-asserted-by":"crossref","first-page":"1","DOI":"10.5070\/D353F8Q915","article-title":"Melanoma costs: a dynamic model comparing estimated overall costs of various clinical stages","volume":"15","author":"Alexandrescu","year":"2009","journal-title":"Dermatol Online J"},{"issue":"14","key":"2023083113304300500_ref20","doi-asserted-by":"crossref","first-page":"2175","DOI":"10.1016\/j.ejca.2012.03.003","article-title":"Economic impact of healthcare resource utilisation patterns among patients diagnosed with advanced melanoma in the United Kingdom, Italy, and France: results from a retrospective, longitudinal survey (MELODY study)","volume":"48","author":"Johnston","year":"2012","journal-title":"Eur J Cancer"},{"issue":"1","key":"2023083113304300500_ref21","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1186\/1756-9966-31-91","article-title":"The cost of unresectable stage III or stage IV melanoma in Italy","volume":"31","author":"Maio","year":"2012","journal-title":"J Exp Clin Cancer Res"},{"issue":"1 Pt 1","key":"2023083113304300500_ref22","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1111\/dsu.12024","article-title":"Analysis of skin cancer treatment and costs in the United States Medicare population, 1996-2008","volume":"39","author":"Rogers","year":"2013","journal-title":"Dermatol Surg"},{"issue":"6","key":"2023083113304300500_ref23","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1097\/CEJ.0b013e328360150c","article-title":"Costs of illness for melanoma and nonmelanoma skin cancer in Denmark","volume":"22","author":"Bentzen","year":"2013","journal-title":"Eur J Cancer Prev"},{"issue":"1","key":"2023083113304300500_ref24","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1093\/pubmed\/fdt032","article-title":"Measuring current and future cost of skin cancer in England","volume":"36","author":"Vallejo-Torres","year":"2014","journal-title":"J Public Health"},{"key":"2023083113304300500_ref25","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1186\/s12889-015-2267-3","article-title":"Estimating the economic costs of skin cancer in New South Wales, Australia","volume":"15","author":"Doran","year":"2015","journal-title":"BMC Public Health"},{"issue":"5","key":"2023083113304300500_ref27","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1111\/jdv.13110","article-title":"Stage-specific direct health care costs in patients with cutaneous malignant melanoma","volume":"30","author":"Lyth","year":"2016","journal-title":"J Eur Acad Dermatol Venereol"},{"key":"2023083113304300500_ref28","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1016\/j.ypmed.2016.10.005","article-title":"Burden of skin cancer in Belgium and cost-effectiveness of primary prevention by reducing ultraviolet exposure","volume":"93","author":"Pil","year":"2016","journal-title":"Prev Med"},{"issue":"8","key":"2023083113304300500_ref29","doi-asserted-by":"crossref","DOI":"10.1136\/bmjopen-2016-014880","article-title":"Multiple treatment comparison of seven new drugs for patients with advanced malignant melanoma: a systematic review and health economic decision model in a Norwegian setting","volume":"7","author":"Pike","year":"2017","journal-title":"BMJ Open"},{"issue":"2","key":"2023083113304300500_ref30","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1001\/jamadermatol.2016.4518","article-title":"Cost-effectiveness and budget effect analysis of a population-based skin cancer screening","volume":"153","author":"Pil","year":"2017","journal-title":"JAMA Dermatol"},{"issue":"3","key":"2023083113304300500_ref31","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.ad.2016.09.010","article-title":"Cost of cutaneous melanoma by tumor stage: a descriptive analysis","volume":"108","author":"Serra-Arbeloa","year":"2017","journal-title":"Actas Dermosifiliogr"},{"issue":"2","key":"2023083113304300500_ref32","doi-asserted-by":"crossref","first-page":"218","DOI":"10.2340\/00015555-2830","article-title":"Estimation of direct melanoma-related costs by disease stage and by phase of diagnosis and treatment according to clinical guidelines","volume":"98","author":"Buja","year":"2018","journal-title":"Acta Derm Venereol"},{"issue":"1","key":"2023083113304300500_ref33","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1186\/s12913-021-06246-1","article-title":"Cutaneous melanoma: cost of illness under Brazilian health system perspectives","volume":"21","author":"Veiga","year":"2021","journal-title":"BMC Health Serv Res"},{"issue":"6","key":"2023083113304300500_ref34","first-page":"764","article-title":"Estimation of direct costs of melanoma in the Veneto Region: a budget assessment and cost-consequence analysis","volume":"155","author":"Buja","year":"2020","journal-title":"G Ital Dermatol Venereol"},{"issue":"6","key":"2023083113304300500_ref35","doi-asserted-by":"crossref","first-page":"730","DOI":"10.1684\/ejd.2021.4149","article-title":"Quality management of cutaneous melanoma: impact on short-term outcomes and costs","volume":"31","author":"Buja","year":"2021","journal-title":"Eur J Dermatol"},{"issue":"5","key":"2023083113304300500_ref36","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.1007\/s13555-022-00715-z","article-title":"Malignant melanoma: direct costs by clinical and pathological profile","volume":"12","author":"Buja","year":"2022","journal-title":"Dermatol Ther"},{"issue":"2","key":"2023083113304300500_ref37","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1007\/s11845-013-0993-z","article-title":"Completeness of case ascertainment at the Irish National Cancer Registry","volume":"183","author":"O'Brien","year":"2014","journal-title":"Ir J Med Sci"},{"issue":"1","key":"2023083113304300500_ref38","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.jaad.2010.09.772","article-title":"Hazard rates for recurrent and secondary cutaneous melanoma: an analysis of 33,384 patients in the German Central Malignant Melanoma Registry","volume":"66","author":"Leiter","year":"2012","journal-title":"J Am Acad Dermatol"},{"key":"2023083113304300500_ref39","volume-title":"Guidelines for the Economic Evaluation of Health Technologies in Ireland","author":"Health Information and Quality Authority","year":"2020"},{"key":"2023083113304300500_ref40","doi-asserted-by":"crossref","first-page":"39","DOI":"10.12688\/hrbopenres.13256.1","article-title":"Unit costs for non-acute care in Ireland 2016\u20142019","volume":"4","author":"Smith","year":"2021","journal-title":"HRB Open Res"},{"issue":"1","key":"2023083113304300500_ref41","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.jval.2021.11.1351","article-title":"Consolidated Health Economic Evaluation Reporting Standards 2022 (CHEERS 2022) statement: updated reporting guidance for health economic evaluations","volume":"25","author":"Husereau","year":"2022","journal-title":"Value Health"}],"container-title":["Journal of Public Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article-pdf\/45\/3\/714\/51275247\/fdac154.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article-pdf\/45\/3\/714\/51275247\/fdac154.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,31]],"date-time":"2023-08-31T09:39:22Z","timestamp":1693474762000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/jpubhealth\/article\/45\/3\/714\/7160043"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5,11]]},"references-count":41,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2023,5,11]]},"published-print":{"date-parts":[[2023,8,28]]}},"URL":"https:\/\/doi.org\/10.1093\/pubmed\/fdac154","relation":{},"ISSN":["1741-3842","1741-3850"],"issn-type":[{"value":"1741-3842","type":"print"},{"value":"1741-3850","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2023,9]]},"published":{"date-parts":[[2023,5,11]]}}}